Does the media refer more to PTGX or COAG?

In the previous week, Protagonist Therapeutics had 22 more articles in the media than Hemab Therapeutics. MarketBeat recorded 24 mentions for Protagonist Therapeutics and 2 mentions for Hemab Therapeutics. Protagonist Therapeutics' average media sentiment score of 0.53 beat Hemab Therapeutics' score of 0.37 indicating that Protagonist Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Protagonist Therapeutics 4 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Hemab Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is SYRE or COAG more profitable?

Hemab Therapeutics' return on equity of 0.00% beat Spyre Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Spyre Therapeutics N/A -30.74% -22.23% Hemab Therapeutics N/A N/A N/A

Does the media favor SYRE or COAG?

In the previous week, Spyre Therapeutics had 21 more articles in the media than Hemab Therapeutics. MarketBeat recorded 23 mentions for Spyre Therapeutics and 2 mentions for Hemab Therapeutics. Spyre Therapeutics' average media sentiment score of 0.62 beat Hemab Therapeutics' score of 0.37 indicating that Spyre Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spyre Therapeutics 8 Very Positive mention(s) 5 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Hemab Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to IONS or COAG?

In the previous week, Ionis Pharmaceuticals had 19 more articles in the media than Hemab Therapeutics. MarketBeat recorded 21 mentions for Ionis Pharmaceuticals and 2 mentions for Hemab Therapeutics. Hemab Therapeutics' average media sentiment score of 0.37 beat Ionis Pharmaceuticals' score of 0.19 indicating that Hemab Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ionis Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Hemab Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is COAG or PRAX more profitable?

Hemab Therapeutics' return on equity of 0.00% beat Praxis Precision Medicines' return on equity. Company Net Margins Return on Equity Return on Assets Hemab Therapeutics N/A N/A N/A Praxis Precision Medicines N/A -34.15% -32.42%

Does the media refer more to COAG or PRAX?

In the previous week, Praxis Precision Medicines had 21 more articles in the media than Hemab Therapeutics. MarketBeat recorded 23 mentions for Praxis Precision Medicines and 2 mentions for Hemab Therapeutics. Praxis Precision Medicines' average media sentiment score of 0.59 beat Hemab Therapeutics' score of 0.37 indicating that Praxis Precision Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hemab Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Praxis Precision Medicines 7 Very Positive mention(s) 3 Positive mention(s) 9 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media prefer KYMR or COAG?

In the previous week, Kymera Therapeutics had 27 more articles in the media than Hemab Therapeutics. MarketBeat recorded 29 mentions for Kymera Therapeutics and 2 mentions for Hemab Therapeutics. Hemab Therapeutics' average media sentiment score of 0.37 beat Kymera Therapeutics' score of -0.19 indicating that Hemab Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kymera Therapeutics 2 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 4 Negative mention(s) 1 Very Negative mention(s) Neutral Hemab Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Hemab Therapeutics (COAG) Competitors

$50.57 +0.91 (+1.83%)

As of 10:32 AM Eastern

Compare

COAG vs. PTGX, SYRE, IONS, PRAX, and KYMR

Should you buy Hemab Therapeutics stock or one of its competitors? MarketBeat compares Hemab Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Hemab Therapeutics include Protagonist Therapeutics (PTGX), Spyre Therapeutics (SYRE), Ionis Pharmaceuticals (IONS), Praxis Precision Medicines (PRAX), and Kymera Therapeutics (KYMR). These companies are all part of the "biotechnology" industry.

How does Hemab Therapeutics compare to Protagonist Therapeutics?

Protagonist Therapeutics (NASDAQ:PTGX) and Hemab Therapeutics (NASDAQ:COAG) are both mid-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, earnings, dividends, profitability, valuation and risk.

Protagonist Therapeutics has a net margin of 29.40% compared to Hemab Therapeutics' net margin of 0.00%. Protagonist Therapeutics' return on equity of 12.03% beat Hemab Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protagonist Therapeutics	29.40%	12.03%	11.23%
Hemab Therapeutics	N/A	N/A	N/A

In the previous week, Protagonist Therapeutics had 22 more articles in the media than Hemab Therapeutics. MarketBeat recorded 24 mentions for Protagonist Therapeutics and 2 mentions for Hemab Therapeutics. Protagonist Therapeutics' average media sentiment score of 0.53 beat Hemab Therapeutics' score of 0.37 indicating that Protagonist Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protagonist Therapeutics	4 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Hemab Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

98.6% of Protagonist Therapeutics shares are held by institutional investors. 5.2% of Protagonist Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Protagonist Therapeutics presently has a consensus price target of $132.14, indicating a potential downside of 11.77%. Hemab Therapeutics has a consensus price target of $48.00, indicating a potential downside of 5.08%. Given Hemab Therapeutics' higher possible upside, analysts clearly believe Hemab Therapeutics is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protagonist Therapeutics	1 Sell rating(s)	0 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	3.00
Hemab Therapeutics	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83

Hemab Therapeutics has lower revenue, but higher earnings than Protagonist Therapeutics. Hemab Therapeutics is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protagonist Therapeutics	$46.02M	209.30	-$130.15M	$1.03	145.41
Hemab Therapeutics	N/A	N/A	N/A	-$23.98	N/A

Summary

Protagonist Therapeutics beats Hemab Therapeutics on 13 of the 14 factors compared between the two stocks.

How does Hemab Therapeutics compare to Spyre Therapeutics?

Spyre Therapeutics (NASDAQ:SYRE) and Hemab Therapeutics (NASDAQ:COAG) are both mid-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, earnings, media sentiment, analyst recommendations, institutional ownership and profitability.

Spyre Therapeutics currently has a consensus target price of $110.15, suggesting a potential upside of 5.01%. Hemab Therapeutics has a consensus target price of $48.00, suggesting a potential downside of 5.08%. Given Spyre Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Spyre Therapeutics is more favorable than Hemab Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyre Therapeutics	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87
Hemab Therapeutics	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83

Hemab Therapeutics' return on equity of 0.00% beat Spyre Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spyre Therapeutics	N/A	-30.74%	-22.23%
Hemab Therapeutics	N/A	N/A	N/A

Hemab Therapeutics has lower revenue, but higher earnings than Spyre Therapeutics. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Hemab Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyre Therapeutics	$890K	10,364.57	-$155.20M	-$1.95	N/A
Hemab Therapeutics	N/A	N/A	N/A	-$23.98	N/A

In the previous week, Spyre Therapeutics had 21 more articles in the media than Hemab Therapeutics. MarketBeat recorded 23 mentions for Spyre Therapeutics and 2 mentions for Hemab Therapeutics. Spyre Therapeutics' average media sentiment score of 0.62 beat Hemab Therapeutics' score of 0.37 indicating that Spyre Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spyre Therapeutics	8 Very Positive mention(s)	5 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Hemab Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

80.4% of Spyre Therapeutics shares are held by institutional investors. 15.7% of Spyre Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Spyre Therapeutics beats Hemab Therapeutics on 10 of the 13 factors compared between the two stocks.

How does Hemab Therapeutics compare to Ionis Pharmaceuticals?

Ionis Pharmaceuticals (NASDAQ:IONS) and Hemab Therapeutics (NASDAQ:COAG) are both mid-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, analyst recommendations, risk, valuation, dividends, media sentiment and institutional ownership.

93.9% of Ionis Pharmaceuticals shares are held by institutional investors. 1.8% of Ionis Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Ionis Pharmaceuticals had 19 more articles in the media than Hemab Therapeutics. MarketBeat recorded 21 mentions for Ionis Pharmaceuticals and 2 mentions for Hemab Therapeutics. Hemab Therapeutics' average media sentiment score of 0.37 beat Ionis Pharmaceuticals' score of 0.19 indicating that Hemab Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ionis Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Hemab Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Ionis Pharmaceuticals presently has a consensus price target of $94.65, suggesting a potential upside of 66.00%. Hemab Therapeutics has a consensus price target of $48.00, suggesting a potential downside of 5.08%. Given Ionis Pharmaceuticals' higher possible upside, research analysts plainly believe Ionis Pharmaceuticals is more favorable than Hemab Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ionis Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	18 Buy rating(s)	0 Strong Buy rating(s)	2.77
Hemab Therapeutics	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83

Hemab Therapeutics has lower revenue, but higher earnings than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than Hemab Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ionis Pharmaceuticals	$874.09M	10.84	-$381.39M	-$3.46	N/A
Hemab Therapeutics	N/A	N/A	N/A	-$23.98	N/A

Hemab Therapeutics has a net margin of 0.00% compared to Ionis Pharmaceuticals' net margin of -64.76%. Hemab Therapeutics' return on equity of 0.00% beat Ionis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ionis Pharmaceuticals	-64.76%	-111.08%	-17.41%
Hemab Therapeutics	N/A	N/A	N/A

Summary

Ionis Pharmaceuticals beats Hemab Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Hemab Therapeutics compare to Praxis Precision Medicines?

Hemab Therapeutics (NASDAQ:COAG) and Praxis Precision Medicines (NASDAQ:PRAX) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, valuation, profitability, media sentiment, analyst recommendations, earnings, institutional ownership and dividends.

Hemab Therapeutics has higher earnings, but lower revenue than Praxis Precision Medicines. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Hemab Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hemab Therapeutics	N/A	N/A	N/A	-$23.98	N/A
Praxis Precision Medicines	$8.55M	1,175.48	-$303.27M	-$12.93	N/A

Hemab Therapeutics' return on equity of 0.00% beat Praxis Precision Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hemab Therapeutics	N/A	N/A	N/A
Praxis Precision Medicines	N/A	-34.15%	-32.42%

In the previous week, Praxis Precision Medicines had 21 more articles in the media than Hemab Therapeutics. MarketBeat recorded 23 mentions for Praxis Precision Medicines and 2 mentions for Hemab Therapeutics. Praxis Precision Medicines' average media sentiment score of 0.59 beat Hemab Therapeutics' score of 0.37 indicating that Praxis Precision Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hemab Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Praxis Precision Medicines	7 Very Positive mention(s)	3 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

Hemab Therapeutics currently has a consensus target price of $48.00, suggesting a potential downside of 5.08%. Praxis Precision Medicines has a consensus target price of $573.05, suggesting a potential upside of 59.19%. Given Praxis Precision Medicines' stronger consensus rating and higher possible upside, analysts clearly believe Praxis Precision Medicines is more favorable than Hemab Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hemab Therapeutics	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83
Praxis Precision Medicines	2 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	4 Strong Buy rating(s)	3.00

67.8% of Praxis Precision Medicines shares are owned by institutional investors. 3.0% of Praxis Precision Medicines shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Praxis Precision Medicines beats Hemab Therapeutics on 10 of the 13 factors compared between the two stocks.

How does Hemab Therapeutics compare to Kymera Therapeutics?

Kymera Therapeutics (NASDAQ:KYMR) and Hemab Therapeutics (NASDAQ:COAG) are both mid-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, dividends, risk, profitability and media sentiment.

Kymera Therapeutics presently has a consensus price target of $125.65, indicating a potential upside of 17.19%. Hemab Therapeutics has a consensus price target of $48.00, indicating a potential downside of 5.08%. Given Kymera Therapeutics' higher probable upside, equities analysts clearly believe Kymera Therapeutics is more favorable than Hemab Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kymera Therapeutics	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83
Hemab Therapeutics	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83

Hemab Therapeutics has a net margin of 0.00% compared to Kymera Therapeutics' net margin of -285.33%. Hemab Therapeutics' return on equity of 0.00% beat Kymera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kymera Therapeutics	-285.33%	-21.22%	-19.21%
Hemab Therapeutics	N/A	N/A	N/A

In the previous week, Kymera Therapeutics had 27 more articles in the media than Hemab Therapeutics. MarketBeat recorded 29 mentions for Kymera Therapeutics and 2 mentions for Hemab Therapeutics. Hemab Therapeutics' average media sentiment score of 0.37 beat Kymera Therapeutics' score of -0.19 indicating that Hemab Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kymera Therapeutics	2 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	4 Negative mention(s)	1 Very Negative mention(s)	Neutral
Hemab Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Hemab Therapeutics has lower revenue, but higher earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Hemab Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kymera Therapeutics	$39.21M	227.37	-$311.35M	-$3.24	N/A
Hemab Therapeutics	N/A	N/A	N/A	-$23.98	N/A

Summary

Hemab Therapeutics beats Kymera Therapeutics on 6 of the 11 factors compared between the two stocks.

Get Hemab Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding COAG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

COAG vs. The Competition

Export

Metric	Hemab Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.36B	$3.71B	$7.02B	$12.96B
Dividend Yield	N/A	3.76%	2.58%	10.20%
P/E Ratio	-2.11	9.07	269.90	24.97
Price / Sales	N/A	1,294.66	659.13	107.89
Price / Cash	N/A	44.95	28.89	37.44
Price / Book	N/A	17.71	11.29	6.44
Net Income	N/A	-$13.25M	$3.45B	$347.50M
7 Day Performance	12.38%	5.42%	3.56%	3.82%
1 Month Performance	32.97%	-1.71%	-0.57%	-0.37%
1 Year Performance	N/A	61.70%	77.67%	23.81%

Hemab Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
COAG Hemab Therapeutics	2.1274 of 5 stars	$50.57 +1.8%	$48.00 -5.1%	N/A	$2.36B	N/A	N/A	72
PTGX Protagonist Therapeutics	1.4777 of 5 stars	$136.64 -1.4%	$123.00 -10.0%	+185.6%	$8.79B	$46.02M	N/A	120	Earnings Report Analyst Downgrade Analyst Revision Gap Up
SYRE Spyre Therapeutics	2.2765 of 5 stars	$98.33 -3.1%	$101.42 +3.1%	+592.0%	$8.65B	$890K	N/A	73	Earnings Report Analyst Upgrade
IONS Ionis Pharmaceuticals	3.7539 of 5 stars	$51.77 -2.8%	$94.85 +83.2%	+35.8%	$8.60B	$944M	N/A	1,402
PRAX Praxis Precision Medicines	3.8367 of 5 stars	$307.83 +0.0%	$563.50 +83.1%	+685.3%	$8.58B	$8.55M	N/A	110	Positive News Earnings Report Analyst Forecast Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:COAG) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Hemab Therapeutics (COAG) Competitors

COAG vs. PTGX, SYRE, IONS, PRAX, and KYMR

How does Hemab Therapeutics compare to Protagonist Therapeutics?

Summary

How does Hemab Therapeutics compare to Spyre Therapeutics?

Summary

How does Hemab Therapeutics compare to Ionis Pharmaceuticals?

Summary

How does Hemab Therapeutics compare to Praxis Precision Medicines?

Summary

How does Hemab Therapeutics compare to Kymera Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

COAG vs. The Competition

Hemab Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Hemab Therapeutics (COAG) Competitors

COAG vs. PTGX, SYRE, IONS, PRAX, and KYMR

How does Hemab Therapeutics compare to Protagonist Therapeutics?

Is PTGX or COAG more profitable?

Does the media refer more to PTGX or COAG?

Do insiders and institutionals have more ownership in PTGX or COAG?

Do analysts rate PTGX or COAG?

Which has higher earnings and valuation, PTGX or COAG?

Summary

How does Hemab Therapeutics compare to Spyre Therapeutics?

Do analysts recommend SYRE or COAG?

Is SYRE or COAG more profitable?

Which has preferable earnings and valuation, SYRE or COAG?

Does the media favor SYRE or COAG?

Do insiders and institutionals hold more shares of SYRE or COAG?

Summary

How does Hemab Therapeutics compare to Ionis Pharmaceuticals?

Do institutionals & insiders have more ownership in IONS or COAG?

Does the media refer more to IONS or COAG?

Do analysts rate IONS or COAG?

Which has higher valuation and earnings, IONS or COAG?

Is IONS or COAG more profitable?

Summary

How does Hemab Therapeutics compare to Praxis Precision Medicines?

Which has higher valuation & earnings, COAG or PRAX?

Is COAG or PRAX more profitable?

Does the media refer more to COAG or PRAX?

Do analysts prefer COAG or PRAX?

Do institutionals & insiders hold more shares of COAG or PRAX?

Summary

How does Hemab Therapeutics compare to Kymera Therapeutics?

Do analysts rate KYMR or COAG?

Is KYMR or COAG more profitable?

Does the media prefer KYMR or COAG?

Which has better earnings & valuation, KYMR or COAG?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

COAG vs. The Competition

Hemab Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools